Cramer's 'Mad Money' Follow-Up: Nov. 4

Every night on "Mad Money," Jim Cramer offers market commentary and general investment advice, and he makes calls on specific stocks, both of his own choosing and in response to viewer requests. He relies on his many years of experience and strong track record, and he takes full responsibility for his calls.

"I never shirk from admitting my mistakes; instead, I dwell on them to learn from them. I change my mind, I take losses, I own up to them," Cramer has said.

Here we track some of his calls from the previous episode of "Mad Money" and find out, at least in the very short term, how the stocks are performing. Keep in mind that Cramer might not have been recommending that viewers take immediate action on a stock. And, of course, it's up to the individual investor to do his or her own homework.

That said, here's how some of the stocks that Cramer talked about on Tuesday's "Mad Money" show fared today.

---

Celgene(CELG Quote): Cramer went head to head with colleague Dan Fitzpatrick over this cancer-fighting stock. Fitzpatrick would buy Celgene only if it fell back to and held at $48. Cramer agreed with Fitzpatrick that there's not a compelling reason to buy the stock for the short term, but he liked it's long-term story. He said he'd also wait till the stock fell to $48.

On Wednesday, Celgene added 19 cents, or 0.4%, to close at $50.89.

Sinovac Biotech(SVA Quote): Cramer said the stock is too speculative and recommended CVS Caremark(CVS Quote), Walgreen(WAG Quote) and Becton Dickinson(BDX Quote) instead.

On Wednesday, Sinovac closed off a penny at $7.90, while CVS added 72 cents, or 2%, to $36.15; Walgreen gained $1.04, or 2.7%, to $39.48; and Becton slid $1.40, or 2%, to $68.51.